TABLE 3.

RT resistance mutations from viruses with SI and NSI phenotypes

Virus	RT inhibitor drug(s)a		RT mutationb
	Present	Past	41 M	44 E	67 D	69 T	70 K	74 L	77 F	98 A	103 K	118 V	151 Q	179 V	181 Y	184 M	215 T	219 K
SI viruses
TC-03	HYD + DDI + AZT	DDI + HYD			N	N	R		L				M				I	E/Q
TC-04	ABC + EFV	D4T + NVP
TC-08	3TC + D4T	AZT												I		V
TC-13	3TC + AZT	DDI + HYD
TC-22	NVP	HYD + DDI + AZT	L								N					V	Y
TC-23	AZT + DDC				G		R											Q
TC-25	EFV	D4T + NVP
TC-28	3TC + AZT				N		R									V	I	Q
TC-29	3TC + AZT		P	V	N		R					I		I		V		Q
TC-30	3TC + AZT														V
NSI viruses
TC-02	3TC + AZT
TC-12	DDI + HYD
TC-19	3TC + AZT		L		N		R									V
TC-26	3TC + AZT	3TC + AZT, 3TC
TC-27	DDI + AZT	AZT	L		N		R			G						V	Y
TC-31	D4T + 3TC		L		N			V							I		Y
TC-32	3TC + AZT	DDI + AZT + EFV														V
TC-33	3TC + AZT	D4T + DDI
TC-35	3TC + AZT	DDC + AZT	L				R									V	Y

^aAbbreviations: HYD, hydroxyurea; DDI, didanosine; AZT, zidovudine; ABC, abacavir; EFV, efavirenz; D4T, stavudine; NVP, nevirapine; 3TC, lamivudine; DDC, zalcitabine.

^bAmino acids and their positions correspond to consensus wild-type subtype B sequence.